16 research outputs found
μ°λ₯΄μλ°μ₯μμ½μ° λΆμμ± μλ°μ± λ΄μ¦μ± λ΄κ΄μΌ νμλ€μμ μΆκ°μ μΈ νμ΄λΈλ μ΄νΈ μΉλ£μ ν¨κ³Όμ λν μ°κ΅¬
νμλ
Όλ¬Έ(μμ¬) -- μμΈλνκ΅λνμ : μκ³Όλν μνκ³Ό, 2023. 2. μ€μ ν.Background & Aims: There is no proven treatment for ursodeoxycholic acid (UDCA) refractory primary biliary cholangitis (PBC) other than obeticholic acid. Although fibrates have been reported to improve biochemical parameters, the longβterm effects remain unclear. This study evaluated the effect of fibrate on clinical outcomes of UDCAβrefractory PBC.
Methods: Patients whose alkaline phosphatase (ALP) was not normalized with at least 13 mg/kg of UDCA treatment for >1 year were included from two tertiary referral centres. The primary outcome was ALP normalization. Secondary outcomes included the development of cirrhosis and hepatic deterioration. Immortal time bias
was adjusted using the MantelβByar method.
Results: A total of 100 UDCAβrefractory PBC patients were included: 71 patients received UDCA alone (the UDCA group) and 29 patients received UDCA plus additional fibrate treatment of 160 mg/d fenofibrate or 400 mg/d bezafibrate (the fibrate/UDCA group). During the followβup period, the probability of ALP normalization was significantly higher in the fibrate/UDCA group (hazard ratio [HR] = 5.00, 95% confidence interval = 2.87-8.27, P < 0.001). Among 58 non cirrhotic patients (43 in the UDCA group and 15 in the fibrate/UDCA group), 19 patients (44.1%) in the UDCA group and none in the fibrate/UDCA group developed cirrhosis (HR = 0.12, P = 0.04). Hepatic deterioration (ChildβPugh score increase or signs of decompensated cirrhosis) occurred in 17 patients (23.9%) of the UDCA group and none in the fibrate/UDCA group in which the difference was significant (HR = 0.12, P = 0.04).
Conclusions: In patients with UDCAβrefractory PBC, additional fibrate treatment is associated with a higher probability of ALP normalization and a lower risk of cirrhosis development and hepatic deterioration.μλ‘ : μμ§κΉμ§ μ°λ₯΄μλ°μ₯μμ½λ¦°μ°μ λΆμνλ μλ°μ± λ΄μ¦μ± λ΄κ΄μΌμ λν μΉλ£λ λͺ
νν ν립λμ§ μμ μν©μ΄λ€. μ¬λ¬ ν보 μ½μ λ€ μ€ νμ΄λΈλ μ΄νΈλ€μ κ²½μ° κ°μμΉλ₯Ό ν¬ν¨ν μννμ μ§νλ€μ νΈμ μ 보μΈλ€λ λ³΄κ³ λ€μ μΌλΆ μμμΌλ, μ₯κΈ°κ° ν¨κ³Όλ€μ λν΄μλ μμ§ λͺ
νν νμΈλ λ°κ° μλ μν©μ΄λ€. μ΄μ λ³Έ μ°κ΅¬μμλ μ°λ₯΄μλ°μ₯μμ½λ¦°μ° λΆμμ± μλ°μ± λ΄μ¦μ± λ΄κ΄μΌ νμλ€μκ² μμ΄ νμ΄λΈλ μ΄νΈ μΉλ£μ μμμ μ§νλ€ κ°μ κ΄κ³λ₯Ό νμΈνκ³ μ νμλ€.
λ°©λ²: λ κ°μ 3μ°¨ λ³μμμ μλ°μ± λ΄μ¦μ± λ΄κ΄μΌμΌλ‘ μ§λ¨λ°κ³ μΉλ£ λ°λ νμλ€ μ€ μΆ©λΆν μ©λ(13mg/kgμ μ°λ₯΄μλ°μ₯μμ½λ¦°μ°)μ 1λ
λκ² μ¬μ©νμμμλ νμ€ μμΉ΄λ¦¬μ± μΈμ°νλΆν΄ν¨μκ° μ μν λμ§ μμ νμλ€μ λμμΌλ‘ μ°κ΅¬κ° μ§νλμλ€. μΌμ°¨ νκ° λ³μλ‘λ μμΉ΄λ¦¬μ± μΈμ°νλΆν΄ν¨μμ μ μν μ¬λΆμμΌλ©°, μ΄μ°¨ νκ° λ³μλ‘λ κ°κ²½ν λ° κ°λΆμ λ°μ μ¬λΆμλ€. μ‘°κΈ°λ°κ²¬κΈ°κ° μ€λ₯μ λ¬Έμ λ₯Ό ν΄κ²°νκΈ° μν΄μ Mantel-Byar λ°©λ²μ νμνμλ€.
κ²°κ³Ό: μ΄ 100λͺ
μ μ°λ₯΄μλ°μ₯μμ½λ¦°μ° λΆμμ± μλ°μ± λ΄μ¦μ± λ΄κ΄μΌ νμλ€μ΄ μ°κ΅¬μ ν¬ν¨λμλ€: 71λͺ
μ νμλ€μ μ°λ₯΄μλ°μ₯μμ½λ¦°μ°λ§ μ²λ°© λ°μμΌλ©°(UDCA κ΅°), 29λͺ
μ νμλ€μ νμ΄λΈλ μ΄νΈλ₯Ό λμ μ²λ°© λ°μλ€(fibrate/UDCA κ΅°). κ΄μ°° κΈ°κ° μ€, fibrate/UDCA κ΅°μμ μμΉ΄λ¦¬μ± μΈμ°νλΆν΄ν¨μ μμΉμ μ μνμ κ°λ₯μ±μ΄ UDCAκ΅°μ λΉν΄μ μ μνκ² λμλ€(μνλ [HR]=5.00, 95% μ λ’°κ΅¬κ° = 2.87-8.27, P<0.001). κ°κ²½λ³μ΄ μλ 58λͺ
μ νμ(UDCA κ΅° 43λͺ
, fibrate/UDCA κ΅° 15λͺ
)λ€μμ 19λͺ
(44.1%)μ νμλ€μμ κ°κ²½λ³μ΄ λ°μνμλλ°, μ΄λ λͺ¨λ UDCA κ΅°μμλ§ λ°μνμλ€(HR=0.12, P=0.04). κ°λΆμ (2μ μ΄μμ μ°¨μΌλ-ν¨ μ μ μ¦κ°, λλ λΉλμμ± κ°κ²½λ³μ λ°μ) λν 17λͺ
(23.9%) μμ λ°μνμλλ°, λͺ¨λ UDCA κ΅°μμλ§ λ°μνμλ€(HR=0.12, P=0.04).
κ²°λ‘ : μ°λ₯΄μλ°μ₯μμ½λ¦°μ° λΆμμ± μλ°μ± λ΄μ¦μ± λ΄κ΄μΌ νμλ€μκ² μμ΄ μΆκ°μ μΈ νμ΄λΈλ μ΄νΈ μΉλ£λ₯Ό νλ κ²½μ°, μμΉ΄λ¦¬μ± μΈμ°νλΆν΄ν¨μμ μ μνμ νλ₯ μ΄ λμμ§λ κ²κ³Ό κ°λΆμ λλ κ°κ²½ν λ°μ κ°μμ μ°κ΄μ±μ΄ μμ΄λ³΄μΈλ€.Introduction 1
Methods 3
Patients 3
Treatment 4
Outcomes and evaluation 4
Statistical analysis 5
Results 8
Baseline characteristics 8
Biochemical normalization 11
Long-term liver-related events 19
Safety 36
Discussion 38
References 43
Abstract 50μ
Generation of CDA R2 entry level using pattern analysis and text processing of clinical documents
νμλ
Όλ¬Έ(μμ¬)--μμΈλνκ΅ λνμ :νλκ³Όμ μμ©μ체곡νμ 곡,2007.Maste
Bone regenerative effects of recombinant human bone morphogenetic protein-2 employed prot
μΉμνκ³Ό/μμ¬[νκΈ]
BMPs(Bone morphogenetic proteins)λ transforming growth factor - Ξ²(TGF-Ξ²) superfamilyμ μνλ 볡ν©κΈ°λ₯μ μ±μ₯μΈμλ‘μ 골과 μ°κ³¨μ νμ±κ³Ό μ¬μμ μ λνλ κ°λ ₯ν μ‘°μ μΈμμ΄λ€. κ·Έλμμ λ§μ μ°κ΅¬λ€μ ν΅νμ¬ Human Recombinant Bone Morphogenetic proteins(rh-BMPs)λ μ΄μλμμλ, μ μ골 λ° μ μμ°κ³¨μ νμ±νλ€κ³ μλ €μ Έ μλ€. μ΅κ·Όμ rh-BMPsμ κ²½μ μ± λ° λλμμ°μ νκ³μ±μ 극볡νκΈ° μν μλκ° μ΄λ€μ§κ³ μλ€. λ°ν
리μλ₯Ό μ΄μ©ν μ¬μ‘°ν© λ¨λ°±μ§ μ λ¬ μμ(PTD)μ μμ°ν΄λΌ κ²½μ° λ€λμ μ체 λ¨λ°±μ§μ μ½κ² μ»μ μ μλ μ₯μ μ΄ μλ€. μ΄μ λ¨λ°±μ§ μ λ¬ μμμ μ΄μ©νμ¬ λ€μν λ¨λ°±μ§μ μΈν¬λ΄λ‘ μ λ¬μν€λ λ°©λ²μ μ΄μ©ν μλ‘μ΄ μΉλ£λ² κ°λ°μ΄ μλλκ³ μλ€.
λ³Έ μ°κ΅¬μ λͺ©μ μ μΈν¬λ΄λ‘ μλ°μ ν¬κ³Όκ° κ°λ₯ν λ¨λ°±μ§ μ λ¬ μμ(protein transduction domain:PTD)μ κ°μ§ HIV-1 ν©νμ΄λλ₯Ό μ΄μ©ν μ¬μ‘°ν© TATBMP-2μ μΆκ°λ‘ HA2λ₯Ό μ½μ
μμΌ λ³νν TAT-HA2-BMP-2λ₯Ό λ°±μμ λκ°κ³¨ κ²°μλΆμ μ΄μνν, 골μ¬μν¨κ³Όλ₯Ό 보λ κ²μ΄λ€. λ³Έ μ°κ΅¬μμλ μ
μ±λ°±μ (Spraque Dawley rat) 32λ§λ¦¬μ λκ°κ³¨μ μ΄μ©νμλ€. 8λ§λ¦¬μ λ°±μλκ°κ³¨ κ²°μλΆμλ μ무μ²μΉλ νμ§ μμμΌλ©°(μμ±λμ‘°κ΅°), 8λ§λ¦¬μ λ°±μλκ°κ³¨ κ²°μλΆμλ collagenλ§μ(μμ±λμ‘°κ΅°), μ€νκ΅° 16λ§λ¦¬μλ κ°κ° 8λ§λ¦¬μ© λ°ν
리μμμ μν©μ± λ° μ μ ν TATBMP-2μ TAT-HA2-BMP-2λ₯Ό 0.1mg/mlμ λλλ‘ collagneμ μ μ
μ΄μνμλ€. 2μ£Ό λ° 8μ£Ό μΉμ κΈ°κ°μ λν μ‘°μ§νμ μΌλ‘ νκ°νμμΌλ©°, λ€μκ³Ό κ°μ κ²°λ‘ μ μ»μ μ μμλ€.
1. TATBMP-2μ 골 μ¬μν¨κ³Όλ μ‘°μ§νμ견μμ μμ±λμ‘°κ΅° λ° μμ±λμ‘°κ΅°μ λΉν΄ λλ ·νμ§ μμλ€.
2. TAT-HA2-BMP-2μ 골 μ¬μν¨κ³Όλ μ‘°μ§ν μ견μ, μμ±λμ‘°κ΅° λ° μμ±λμ‘°κ΅°, TATBMP-2κ΅°κ³Ό λΉκ΅νμ¬ μΌλΆκ°μ²΄μμ λͺ
νν 골νμ±μ΄ λνλ¬λ€.
λ³Έ μ°κ΅¬μΈ λ°±μ λκ°κ³¨ κ²°μλΆμμ PTDBMP-2μΈ TATBMP-2μ TAT-HA2-BMP-2λ₯Ό collagenμ μ λ¬μ²΄λ‘ νμ¬ 0.1 mg/mlμ λλλ‘ μ μ©μμΌ λ³΄μμκ²½μ° TATBMP-2μ 골μ¬μν¨κ³Όλ λ―Έλ―Ένμκ³ , TAT-HA2-BMP-2κ΅°μμ κ³¨μ΄ λλ ·μ΄ νμ±λ κ°μ²΄κ° μμλ€. νμ§λ§, λͺ¨λ κ°μ²΄μμ μΌκ΄μ μΈ κ²°κ³Όλ₯Ό 보μ΄μ§ λͺ»νλ€. μ΄μ TAT - HA2 -BMP2λ₯Ό λ³΄λ€ κ· μΌνκ² νμ°μμΌ, λͺ©νλ‘ νλ μΈν¬μ μ μ©ν μ μλ λ°©λ²μ λν μΆκ°μ μΈ μ°κ΅¬κ° νμνλ¦¬λΌ μ¬λ£λλ€.
[μλ¬Έ]
Bone morphogenetic proteins(BMPs) are regarded as members of the transforming growth factor-Ξ² superfamily with characteristic features in their amino acid sequences. A number of studies have demonstrated the biologic activities of BMPs, which include the induction of cartilage and bone formation. Recently there was a attempt to overcome a limitation of mass production, and economical efficieny of rh-BMPs. The method producing PTD by using bacteria have advantages of acquiry a mass of proteins. Hences, a new treatment which deliver protein employed by protein transduction domain(PTD) has been tried.
The purpose of this study was to evaluate the bone regenerative effect of TATBMP-2 and TAT-HA2-BMP-2 employed by PTD from HIV-1 TAT protein for protein translocation in the rat calvarial model. An 8mm calvarial, critical size osteotomy defect was created in each of 32 male Spraque-Dawley rats(weight 250~300g). The animals were divided into 4 groups of 32 animals each (4 animals/group/healing interval). The defect was treated with TATBMP-2/ACS(Absorbable collagen sponge) (TATBMP-2 0.1 mg/ml) , TAT-HA2-BMP-2/ACS(TAT-HA2-BMP-2 0.1mg/ml) , ACS alone or left untreated for surgical control(negative control). The rats were sacrificed at 2 or 8 weeks postsurgery, and the results were evaluated histologically. The results were as follows:
1.New bone formation were not significantly greater in the TATBMP-2/ACS group relative to negative, and positive control groups.
2.New bone was evident at the defect sites in TAT-HA2-BMP-2/ACS group relative to negative, positive control and TATBMP-2 groups.
There were a little bone regeneration in TATBMP-2 groups. While, enhanced local bone formation were observed in TAT-HA2-BMP-2 group. But, The results was not the same in all rat defects. Therefore, further investigations are required to develop a method, which disperse homogenously, and adhere to target cells.ope
Development of an algorithm for multi-plant production plans in a supply chain
νμλ
Όλ¬Έ(λ°μ¬)--μμΈλνκ΅ λνμ :μ°μ
곡νκ³Ό,2005.Docto
μν 5μΆ λ°λ§ λ¨Έμ μ κ°λ°μ κ΄ν μ°κ΅¬
νμλ
Όλ¬Έ(μμ¬)--μμΈλνκ΅ λνμ :κΈ°κ³ν곡곡νλΆ,2002.Maste
One-Warehouse multi-retailer λͺ¨λΈμμ μ 보 곡μ νκ²½νμ μ¬μ£Όλ¬Έμ κ²°μ μ κ΄ν μ°κ΅¬
νμλ
Όλ¬Έ(μμ¬)--μμΈλνκ΅ λνμ :μ°μ
곡νκ³Ό,2000.Maste